By Brad Larson, Director, Drug Product Global Sales & Business Development at Samsung Biologics
During drug development, converting an unformulated active substance into a safe and high-quality final product requires several technical decisions, including primary container selection (a complex and multifaceted decision in and of itself), choice of excipients, and more. Implementing precisely tailored, service-optimized aseptic fill/finish processes, specifically, is crucial for mitigating risks and achieving desired product outcomes.
Today, a plethora of contract development and manufacturing organizations (CDMOs) provide aseptic fill/finish services around the world. However, to offer customers both favorable outcomes and exceptional value, a CDMO must make the curation and integration of deep market intelligence a core part of its service offering.